Technical analysis of Xenon Pharmaceuticals Inc. (XENE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Price Performance
| 1 month | -1.60% |
| 3 months | -39.91% |
| Year-to-date | -16.53% |
| 1 year | -10.76% |
| 3 years | +13.12% |
| 5 years | +9.77% |
| 10 years | +385.84% |
52-Week Range
| 52-week High | $72.66 |
| 52-week Low | $33.41 |
| Avg Volume (90d) | 1.5M |
Technical Indicators
| SMA 50 | $45.35 |
| SMA 200 | $52.37 |
| Beta | 0.74 |
| 30-day Volatility (annualised) | 41.0% |
| Price vs SMA 50 | -17.5% |
| Price vs SMA 200 | -28.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $44.82 | |
| 2026-01 | $41.01 | -8.5% |
| 2026-02 | $43.23 | +5.4% |
| 2026-03 | $58.15 | +34.5% |
| 2026-04 | $56.04 | -3.6% |
| 2026-05 | $54.73 | -2.3% |
| 2026-06 | $60.36 | +10.3% |
| 2026-07 | $62.67 | +3.8% |
| 2026-08 | $60.22 | -3.9% |
| 2026-09 | $37.19 | -38.2% |
| 2026-10 | $37.41 | +0.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-02 | $-1.13 | $1M |
| 2026-08-06 | $-1.14 | $2M |
| 2026-05-07 | $-1.17 | $1M |
| 2026-02-26 | $-1.20 | |
| 2025-11-03 | $-1.16 | |
| 2025-08-11 | $-1.03 | |
| 2025-05-12 | $-0.94 | $2M |
Price
| Price | $37.41 (closing price, October 30, 2026) |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 3.00 |
| EV / EBITDA | -8.43 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.02 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.94 |